You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Claims for Patent: 10,596,167


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,596,167
Title:Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Abstract:Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):Herriot Tabuteau
Assignee: Antecip Bioventures II LLC
Application Number:US16/133,553
Patent Claims: 1. A method, comprising treating a human being with dextromethorphan by administering once daily or twice daily for at least eight consecutive days a single dosage form comprising both dextromethorphan and bupropion to the human being, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the dosage form contains about 40 mg to about 100 mg of dextromethorphan and the weight ratio of dextromethorphan to bupropion is about 0.2 to about 1.0, and wherein after eight consecutive days of administering the dosage form once daily or twice daily, the method results in an AUC0-12 of dextromethorphan that is: 1) at least about 500 ng·hr/mL and 2) at least 15 times the AUC0-12 of dextromethorphan that would be achieved by administering the same amount of dextromethorphan once daily or twice daily without bupropion for eight consecutive days.

2. The method of claim 1, wherein the dosage form is an oral dosage form.

3. The method of claim 1, wherein the dosage form is a solid dosage form that further comprises a binder.

4. The method of claim 1, wherein the dosage form is a solid dosage form that further comprises a disintegrating agent.

5. The method of claim 1, wherein the dosage form is a solid dosage form that further comprises a lubricant.

6. The method of claim 1, wherein the dosage form comprises a liquid or solid phase dispersion of bupropion and dextromethorphan.

7. The method of claim 1, wherein the dosage form is effective for immediate release of dextromethorphan.

8. The method of claim 1, wherein the dosage form is effective for sustained release of bupropion.

9. The method of claim 1, wherein after eight consecutive days of administering the dosage form once daily or twice daily, the AUC0-12 of dextromethorphan is about 500 ng·hr/mL to about 600 ng·hr/mL.

10. The method of claim 1, wherein after eight consecutive days of administering the dosage form once daily or twice daily, the AUC0-12 of dextromethorphan is about 800 ng·hr/mL to about 900 ng·hr/mL.

11. The method of claim 1, wherein after eight consecutive days of administering the dosage form once daily or twice daily, the AUC0-12 of dextromethorphan is at least about 20 times the AUC0-12 of dextromethorphan that would be achieved by administering the same amount of dextromethorphan once daily or twice daily without bupropion for eight consecutive days.

12. The method of claim 1, wherein the once daily or twice daily administration of the dosage form results in a total daily dose of bupropion that is about 150 mg to about 200 mg.

13. The method of claim 1, wherein the once daily or twice daily administration of the dosage form results in a total daily dose of bupropion that is about 200 mg to about 250 mg.

14. The method of claim 1, wherein the once daily or twice daily administration of the dosage form results in a total daily dose of bupropion that is about 250 mg to about 300 mg.

15. The method of claim 1, wherein the once daily or twice daily administration of the dosage form results in a total daily dose of dextromethorphan that is about 60 mg to about 100 mg.

16. A method for treating a human being with dextromethorphan, comprising administering to the human being a combination of dextromethorphan and bupropion in a single dosage form once daily or twice daily for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan, wherein the dosage form contains about 40 mg to about 100 mg of dextromethorphan and the weight ratio of dextromethorphan to bupropion is about 0.2 to about 1.0, and wherein, after the combination is administered once daily or twice daily for eight consecutive days: 1) the human being has a Cmax of dextromethorphan that is at least about 40 ng/mL and 2) the Cmax of dextromethorphan is at least about 15 times the Cmax of dextromethorphan that would result from administering the same amount of dextromethorphan once daily or twice daily without bupropion for eight consecutive days.

17. The method of claim 16, wherein the Cmax of dextromethorphan on the eighth day that the combination is administered is at least about 20 times the Cmax of dextromethorphan that would result from administering the same amount of dextromethorphan once daily or twice daily without bupropion for eight consecutive days.

18. The method of claim 16, wherein the Cmax of dextromethorphan on the eighth day that the combination is administered is about 50 ng/mL to about 60 ng/mL.

19. The method of claim 16, wherein the Cmax of dextromethorphan on the eighth day that the combination is administered is about 80 ng/mL to about 90 ng/mL.

20. The method of claim 16, wherein the single dosage form containing the combination is an oral dosage form.

21. The method of claim 16, wherein the single dosage form containing the combination is a solid oral dosage form that further comprises a binder.

22. The method of claim 16, wherein the single dosage form containing the combination is a solid oral dosage form that further comprises a disintegrating agent.

23. The method of claim 16, wherein the single dosage form containing the combination is a solid oral dosage form that further comprises a lubricant.

24. The method of claim 16, wherein the single dosage form containing the combination is a solid oral dosage form that is effective for immediate release of dextromethorphan and sustained release of bupropion.

25. The method of claim 20, wherein the once daily or twice daily administration of the combination results in a total daily dose of bupropion that is about 200 mg to about 250 mg.

26. The method of claim 20, wherein the once daily or twice daily administration of the combination results in a total daily dose of dextromethorphan that is about 60 mg to about 100 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.